undamentalytics Newsletter
Sign in

Hedge fund

Ecor1 Capital, LLC

13F for the quarter to June 30, 2026, filed August 14, 2026 · SEC CIK 1587114

Reported value
$2.0bn
100% in companies we cover
Positions we cover
29
Largest ZYME 29.8%
Copy, a year
+1.3%
S&P 500 +13.4%
Copy Sharpe ratio
0.18
S&P 500 0.71

How copying its 13F would have done

$5.0k$10.0k$20.0k$40.0k 201520172019202120232025 $43.5k$11.6k
CopyS&P 500 $10,000 copying Ecor1 Capital, LLC's filed holdings in companies we cover from February 20, 2015, buying on the first trading day after each 13F was filed and holding until the next, against the S&P 500 (total return). Marked weekly, log scale. Before costs and taxes; misses trading within each quarter and anything 13F does not show (shorts, cash, bonds, non-US holdings).

Biggest drop −78.7% (S&P 500 −31.8%); beta 1.06; alpha −4.2% a year (t = −0.36); last 12 months +30.7% against +12.1%.

Reported value by quarter

Ecor1 Capital, LLC: 13F reported value Total value of all positions in each quarter's 13F, as filed (values before 2023 were filed in thousands of dollars and are converted).
$0 $1T $2T $3T $4T Reported value, 2014-12-31: $170.4M Reported value, 2015-03-31: $245.8M Reported value, 2015-06-30: $259.3M Reported value, 2015-09-30: $194M Reported value, 2015-12-31: $248.4M Reported value, 2016-03-31: $229.1M Reported value, 2016-06-30: $218.5M Reported value, 2016-09-30: $261.6M Reported value, 2016-12-31: $283.8M Reported value, 2017-03-31: $339.7M Reported value, 2017-06-30: $433.5M Reported value, 2017-09-30: $730.3M Reported value, 2017-12-31: $745.7M Reported value, 2018-03-31: $933.3M Reported value, 2018-06-30: $914.7M Reported value, 2018-09-30: $966.2M Reported value, 2018-12-31: $869.3M Reported value, 2019-03-31: $923.8M Reported value, 2019-06-30: $970.4M Reported value, 2019-09-30: $749.4M Reported value, 2019-12-31: $1.1B Reported value, 2020-03-31: $957.2M Reported value, 2020-06-30: $1.3B Reported value, 2020-09-30: $1.4B Reported value, 2020-12-31: $1.8B Reported value, 2021-03-31: $2.2B Reported value, 2021-06-30: $2.7B Reported value, 2021-09-30: $2.8B Reported value, 2021-12-31: $3.1B Reported value, 2022-03-31: $3.2B Reported value, 2022-06-30: $2.9B Reported value, 2022-09-30: $3.4B Reported value, 2022-12-31: $3.3T Reported value, 2023-03-31: $3.1B Reported value, 2023-06-30: $3.8B Reported value, 2023-09-30: $2.9B Reported value, 2023-12-31: $3.9B Reported value, 2024-03-31: $3.9B Reported value, 2024-06-30: $3.3B Reported value, 2024-09-30: $2.9B Reported value, 2024-12-31: $2.5B Reported value, 2025-03-31: $1.7B Reported value, 2025-06-30: $1.7B Reported value, 2025-09-30: $2.1B Reported value, 2025-12-31: $2.2B Reported value, 2026-03-31: $2.3B Reported value, 2026-06-30: $2B 2014-12-31 2017-06-30 2019-12-31 2022-06-30 2026-06-30 $2B
View chart data
Period Reported value
2014-12-31 $170.4M
2015-03-31 $245.8M
2015-06-30 $259.3M
2015-09-30 $194M
2015-12-31 $248.4M
2016-03-31 $229.1M
2016-06-30 $218.5M
2016-09-30 $261.6M
2016-12-31 $283.8M
2017-03-31 $339.7M
2017-06-30 $433.5M
2017-09-30 $730.3M
2017-12-31 $745.7M
2018-03-31 $933.3M
2018-06-30 $914.7M
2018-09-30 $966.2M
2018-12-31 $869.3M
2019-03-31 $923.8M
2019-06-30 $970.4M
2019-09-30 $749.4M
2019-12-31 $1.1B
2020-03-31 $957.2M
2020-06-30 $1.3B
2020-09-30 $1.4B
2020-12-31 $1.8B
2021-03-31 $2.2B
2021-06-30 $2.7B
2021-09-30 $2.8B
2021-12-31 $3.1B
2022-03-31 $3.2B
2022-06-30 $2.9B
2022-09-30 $3.4B
2022-12-31 $3.3T
2023-03-31 $3.1B
2023-06-30 $3.8B
2023-09-30 $2.9B
2023-12-31 $3.9B
2024-03-31 $3.9B
2024-06-30 $3.3B
2024-09-30 $2.9B
2024-12-31 $2.5B
2025-03-31 $1.7B
2025-06-30 $1.7B
2025-09-30 $2.1B
2025-12-31 $2.2B
2026-03-31 $2.3B
2026-06-30 $2B

Holdings and moves

CompanyShare of portfolioValueSharesChange in shares
ZYMEZymeworks Inc.29.77%$600.4m22.97M0.0%
ANABAnaptysbio, Inc26.37%$531.9m7.88M0.0%
AKTSAktis Oncology, Inc.7.71%$155.5m4.82M0.0%
CGONCG Oncology, Inc.5.26%$106.2m1.49M+35.6% Added
ETONEton Pharmaceuticals, Inc.3.90%$78.6m2.17M0.0%
CRSPCrispr Therapeutics AG3.76%$75.8m1.39M0.0%
ORICOric Pharmaceuticals, Inc.3.61%$72.9m6.73M0.0%
TRAXFirst Tracks Biotherapeutics, Inc.3.17%$63.9m3.17MNew
LKFTLakefront Biotherapeutics NV2.48%$50.0m1.67M0.0%
NGNENeurogene Inc.1.98%$40.0m1.27M0.0%
STOKStoke Therapeutics, Inc.1.19%$24.0m735.0K+635.0% Added
FULCFulcrum Therapeutics, Inc.1.19%$24.0m6.55MNew
LEGNLegend Biotech Corp1.15%$23.1m800.0KNew
BBOTBridgebio Oncology Therapeutics, Inc.1.07%$21.5m2.82M0.0%
MBXMBX Biosciences, Inc.1.06%$21.4m388.5K−50.0% Reduced
ZBIOZenas Biopharma, Inc.0.99%$20.0m789.5K0.0%
ATRAAtara Biotherapeutics, Inc.0.88%$17.8m1.55M+1458.3% Added
RLAYRelay Therapeutics, Inc.0.65%$13.1m697.9K−63.4% Reduced
AURAAura Biosciences, Inc.0.59%$11.8m1.67MNew
ODTXOdyssey Therapeutics, Inc.0.52%$10.4m555.6KNew
EIKNEikon Therapeutics, Inc.0.47%$9.6m732.6K0.0%
PHVSPharvaris N.V.0.40%$8.1m235.0KNew
ZURAZura Bio Ltd0.34%$7.0m1.18M0.0%
PHATPhathom Pharmaceuticals, Inc.0.34%$6.8m625.0K0.0%
NRIXNurix Therapeutics, Inc.0.33%$6.6m270.0KNew
ERASErasca, Inc.0.30%$6.0m330.0K−63.3% Reduced
ELOXEloxx Pharmaceuticals, Inc.0.28%$5.6m400.0KNew
AARDAardvark Therapeutics, Inc.0.11%$2.3m396.2KNew
MREOMereo Biopharma Group plc0.02%$317,7001.00M−92.5% Reduced
CompanyBought (value)Shares
TRAXFirst Tracks Biotherapeutics, Inc.$63.9m3.17M
CGONCG Oncology, Inc.$27.9m392.3K
FULCFulcrum Therapeutics, Inc.$24.0m6.55M
LEGNLegend Biotech Corp$23.1m800.0K
STOKStoke Therapeutics, Inc.$20.8m635.0K
ATRAAtara Biotherapeutics, Inc.$16.7m1.45M
AURAAura Biosciences, Inc.$11.8m1.67M
ODTXOdyssey Therapeutics, Inc.$10.4m555.6K
PHVSPharvaris N.V.$8.1m235.0K
NRIXNurix Therapeutics, Inc.$6.6m270.0K
ELOXEloxx Pharmaceuticals, Inc.$5.6m400.0K
AARDAardvark Therapeutics, Inc.$2.3m396.2K

Change in shares on the previous quarter's 13F, valued at this quarter's reported price.

CompanySold (value)Shares
JAZZJazz Pharmaceuticals plc−$322.6m−1.71M
XNCRXencor Inc−$26.3m−2.18M
RLAYRelay Therapeutics, Inc.−$22.6m−1.21M
MBXMBX Biosciences, Inc.−$21.4m−388.5K
ERASErasca, Inc.−$10.4m−570.0K
REPLReplimune Group, Inc.−$7.7m−1.00M
MREOMereo Biopharma Group plc−$3.9m−12.37M
PRLDPrelude Therapeutics Inc−$3.2m−947.0K
IBIOIbio, Inc.−$3.0m−1.58M

Change in shares on the previous quarter's 13F, valued at this quarter's reported price.

CompanyValue last quarterShares
JAZZJazz Pharmaceuticals plc$322.6m1.71M
XNCRXencor Inc$26.3m2.18M
REPLReplimune Group, Inc.$7.7m1.00M
PRLDPrelude Therapeutics Inc$3.2m947.0K
IBIOIbio, Inc.$3.0m1.58M
  • Health Care100.0%

Share of the value held in companies we cover, by sector.

PeriodCopy, a yearS&P 500SharpeS&P 500Biggest dropBeta
Whole backtestFebruary 20, 2015 to November 2, 2026+1.3%+13.4%0.180.71−78.7%1.06
2018 onwardsJanuary 5, 2018 to November 2, 2026−2.0%+13.9%0.060.66−78.7%1.02
Last three yearsNovember 3, 2023 to November 2, 2026+8.0%+21.8%0.271.16−58.0%1.12
Last yearNovember 7, 2025 to November 2, 2026+48.8%+14.2%1.340.84−19.3%0.56

From SEC Form 13F data sets. A 13F lists long positions in US-listed shares at the quarter's end, filed up to 45 days later; it does not show shorts, cash, bonds, non-US holdings or trades within the quarter. Positions in companies outside our coverage are not listed here. Research, not investment advice.